Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Huazhi Rougan granule** is an oral, multi-herb traditional Chinese medicine prescription product marketed in China as **Ganqing** for nonalcoholic simple fatty liver associated with the traditional Chinese medicine damp-heat obstruction syndrome. Its labeled therapeutic functions are described as clearing heat and dampness, detoxifying turbidity, promoting resolution of blood stasis, and softening/protecting the liver. The formulation contains 16 processed botanical and fungal materia medica ingredients and is manufactured by Shandong New Time Pharmaceutical. Post-marketing Phase IV studies have evaluated it in nonalcoholic simple fatty liver. Preclinical mouse and systems-pharmacology research suggests potential effects on hepatic lipid accumulation and gut-microbiota composition, but no single validated molecular target has been established for the complete formula. ([lunan.com.cn](https://www.lunan.com.cn/Product/Product/detail/id/111))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huazhi rougan granule.